Literature DB >> 15276173

Clinical and research validity of hadrontherapy with ion beams.

Roberto Orecchia1, Marco Krengli, Barbara A Jereczek-Fossa, Silvia Franzetti, Jean Pierre Gerard.   

Abstract

Clinical results obtained with hadrontherapy have been extremely positive for various tumours, with percentages of local control and survival higher than those ascribed to conventional radiotherapy. Most clinical data obtained with charged particles are related to protontherapy but the implementation of carbon ion therapy has demonstrated to be of great interest in the last decade. These results, accompanied by the new performances in accelerator technology and calculation systems of the delivered doses, have determined over the past years an increased interest for the development of hadrontherapy, with the construction of new centres provided with equipment entirely dedicated to clinical activity (LLUMC, Loma Linda and NPTC, Boston in USA, HIMAC-NIRS, Chiba, PROBEAT, Tsukuba, and Hyogo Beam Medical Centres in Japan). A revision of the clinical indications specifically focused on ion therapy is presented as well as the results obtained in the different centres. With hadrontherapy, it is finally possible to increase the spectrum of treatments allowing preserving the organ and its functionality, with positive impacts from a social and economic point of view.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276173     DOI: 10.1016/j.critrevonc.2004.04.005

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  6 in total

1.  A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy - including photon and proton therapy - for the treatment of radioresistant tumors: the ETOILE trial.

Authors:  Jacques Balosso; Olivia Febvey-Combes; Annie Iung; Hélène Lozano; Abdoulkader Soumai Alloh; Catherine Cornu; Magali Hervé; Zohra Akkal; Michel Lièvre; Valérie Plattner; Francesca Valvo; Cristina Bono; Maria Rosaria Fiore; Viviana Vitolo; Barbara Vischioni; Stéphanie Patin; Hubert Allemand; François Gueyffier; Jennifer Margier; Pascale Guerre; Sylvie Chabaud; Roberto Orecchia; Pascal Pommier
Journal:  BMC Cancer       Date:  2022-05-23       Impact factor: 4.638

2.  A Monte Carlo-based treatment-planning tool for ion beam therapy.

Authors:  T T Böhlen; J Bauer; M Dosanjh; A Ferrari; T Haberer; K Parodi; V Patera; A Mairani
Journal:  J Radiat Res       Date:  2013-07       Impact factor: 2.724

3.  Radiosensitizing Effect of Gadolinium Oxide Nanocrystals in NSCLC Cells Under Carbon Ion Irradiation.

Authors:  Feifei Li; Zihou Li; Xiaodong Jin; Yan Liu; Ping Li; Zheyu Shen; Aiguo Wu; Xiaogang Zheng; Weiqiang Chen; Qiang Li
Journal:  Nanoscale Res Lett       Date:  2019-10-21       Impact factor: 4.703

4.  Epidemiological study of the incidence of cancers eligible for proton or carbon ions therapy: methodology and results of recruitment estimation.

Authors:  Stéphanie Patin; Pascal Pommier; Hu Yi; Marie Hélène Baron; Jacques Balosso
Journal:  J Cancer Epidemiol       Date:  2013-06-20

5.  Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon- and oxygen ion beams.

Authors:  Ivana Dokic; Andrea Mairani; Martin Niklas; Ferdinand Zimmermann; Naved Chaudhri; Damir Krunic; Thomas Tessonnier; Alfredo Ferrari; Katia Parodi; Oliver Jäkel; Jürgen Debus; Thomas Haberer; Amir Abdollahi
Journal:  Oncotarget       Date:  2016-08-30

6.  Potential lethal damage repair in glioblastoma cells irradiated with ion beams of various types and levels of linear energy transfer.

Authors:  Ming Tsuey Chew; Andrew Nisbet; Masao Suzuki; Naruhiro Matsufuji; Takeshi Murakami; Bleddyn Jones; David A Bradley
Journal:  J Radiat Res       Date:  2019-01-01       Impact factor: 2.724

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.